CA3085255A1 - Eif4e-inhibiting compounds and methods - Google Patents

Eif4e-inhibiting compounds and methods Download PDF

Info

Publication number
CA3085255A1
CA3085255A1 CA3085255A CA3085255A CA3085255A1 CA 3085255 A1 CA3085255 A1 CA 3085255A1 CA 3085255 A CA3085255 A CA 3085255A CA 3085255 A CA3085255 A CA 3085255A CA 3085255 A1 CA3085255 A1 CA 3085255A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
mmol
cancer
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3085255A
Other languages
English (en)
French (fr)
Inventor
Samuel Sperry
Alan X. Xiang
Justin T. Ernst
Siegfried H. Reich
Mike SHAGHAFI
Theo Michels
Christian NILEWSKI
Chinh Viet Tran
Garrick Kenneth Packard
Alan Grubbs
Kaveri URKALAN
Takasuke MUKAIYAMA
Paul A. Sprengeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Effector Therapeutics Inc
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of CA3085255A1 publication Critical patent/CA3085255A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3085255A 2019-07-02 2020-06-30 Eif4e-inhibiting compounds and methods Pending CA3085255A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
US62/869662 2019-07-02

Publications (1)

Publication Number Publication Date
CA3085255A1 true CA3085255A1 (en) 2021-01-02

Family

ID=71614984

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3085255A Pending CA3085255A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting compounds and methods
CA3188446A Pending CA3188446A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3188446A Pending CA3188446A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Country Status (15)

Country Link
US (2) US11286268B1 (https=)
EP (1) EP3994139A1 (https=)
JP (1) JP7595055B2 (https=)
KR (1) KR20220061945A (https=)
CN (1) CN114269756B (https=)
AR (1) AR119339A1 (https=)
AU (1) AU2020299362B2 (https=)
BR (1) BR112021026682A2 (https=)
CA (2) CA3085255A1 (https=)
CL (1) CL2021003573A1 (https=)
IL (1) IL289456A (https=)
PY (1) PY2031844A (https=)
TW (1) TWI748541B (https=)
UY (1) UY38773A (https=)
WO (1) WO2021003157A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
JP2023554521A (ja) 2020-12-22 2023-12-27 ファイザー・インク Ｅｉｆ４ｅ阻害剤の固体形態
JP2025539263A (ja) * 2022-11-10 2025-12-04 リボメトリックス，インコーポレイティド ｅＩＦ４Ｅ阻害剤としての化合物及び組成物、ならびにそれらの使用
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為ｅＩＦ４Ｅ抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20110065671A1 (en) * 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014179237A1 (en) 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1
WO2015120350A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法

Also Published As

Publication number Publication date
CN114269756A (zh) 2022-04-01
CA3188446A1 (en) 2021-01-07
AU2020299362A1 (en) 2022-02-24
PY2031844A (es) 2021-04-19
TWI748541B (zh) 2021-12-01
JP7595055B2 (ja) 2024-12-05
WO2021003157A1 (en) 2021-01-07
IL289456A (en) 2022-02-01
JP2022539256A (ja) 2022-09-07
KR20220061945A (ko) 2022-05-13
AR119339A1 (es) 2021-12-09
UY38773A (es) 2021-01-29
BR112021026682A2 (pt) 2022-03-15
CL2021003573A1 (es) 2022-08-12
US11286268B1 (en) 2022-03-29
TW202115058A (zh) 2021-04-16
CN114269756B (zh) 2024-05-14
EP3994139A1 (en) 2022-05-11
US20230108594A1 (en) 2023-04-06
AU2020299362B2 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
CA3085255A1 (en) Eif4e-inhibiting compounds and methods
US9814718B2 (en) MNK inhibitors and methods related thereto
CA2927252C (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
KR102677015B1 (ko) Bet 억제제로서의 헤테로시클릭 화합물
TWI499420B (zh) 肌醇磷脂３-激酶抑制劑化合物及使用方法
US10988476B2 (en) Substituted pyrimidines as cyclin-dependent kinase inhibitors
CA3002877A1 (en) Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
TW202023559A (zh) 吡化合物及其用途
JP6888006B2 (ja) Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
BRPI1012159A2 (pt) derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase.
US20250144094A1 (en) Thiophene ulk1/2 inhibitors and their use thereof
JP2022526831A (ja) ヘテロ環式化合物およびその使用
WO2023215494A1 (en) Thiophene ulk1/2 inhibitors and their use thereof
CN115181092B (zh) 吡嗪化合物和其用途
TW201305153A (zh) 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240313

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250711